Rituximab in Polymyositis
Rituximab should be used in adult patients with polymyositis who have refractory disease after failing conventional therapy with corticosteroids and at least one steroid-sparing agent (methotrexate, azathioprine, or mycophenolate mofetil), or in those with severe disease complications including significant organ involvement. 1
Indications for Rituximab
Rituximab is positioned as an alternative to cyclophosphamide for patients with:
- Refractory polymyositis that has not responded to high-dose corticosteroids combined with conventional immunosuppressants 1
- Severe disease complications, particularly pulmonary involvement or other organ manifestations 1
- Inability to taper corticosteroids despite adequate trial of steroid-sparing agents
The evidence shows that 83% of patients with refractory myositis demonstrated favorable response and improvement throughout a 44-week trial 1. Real-world data confirms that over 90% of patients achieved at least minimal improvement at 12 months, with significant corticosteroid dose reduction from 15 mg to 5 mg daily 2.
Recommended Dosing Protocol
Standard dosing for adults: Two doses of 1000 mg intravenous rituximab separated by 2 weeks 1
Alternative dosing regimen: 375 mg/m² once weekly for 4 weeks 1
Recent evidence suggests that lower doses may be equally effective:
- Two doses of 500 mg separated by 2 weeks showed comparable efficacy to the 1000 mg regimen at 6 and 12 months 3
- Ultra-low dose (100 mg) has been studied in specific contexts but is not standard 4
The Mayo Clinic guideline clearly states the standard approach is two 1000-mg doses given 2 weeks apart for adults 1.
Pre-Treatment Screening Requirements
Mandatory baseline testing before rituximab administration: 1
- Immunoglobulin levels (IgG, IgM, IgA)
- Hepatitis B surface antigen and antibody levels
- Hepatitis C antibody levels
- Tuberculosis screening (QuantiFERON or PPD)
Monitoring Protocol
During infusion:
- Premedicate with acetaminophen and antihistamine before each infusion 5
- Methylprednisolone 100 mg IV (or equivalent) 30 minutes prior to infusion 5
Post-treatment monitoring:
- B-cell depletion typically occurs within 7 days and can last 15-18 months on average 6
- Monitor for B-cell return (CD19+ counts), as myositis may recur when circulating B cells return 1
- Serial assessment of muscle strength, CK levels, and functional status
- Immunoglobulin levels should be monitored, though severe hypogammaglobulinemia (IgG <400 mg/dL) is uncommon 2
Re-treatment considerations:
- Clinical relapse may occur 6-10 months post-infusion and does not always correlate with CD19+ cell levels 7
- Re-treatment can be administered when clinical symptoms return, typically not sooner than 16 weeks after the previous infusion 5
Critical Safety Concerns
Progressive multifocal leukoencephalopathy (PML):
- Has been reported in rheumatic patients treated with rituximab 1
- Importantly, PML has also been reported in myositis patients who were NOT treated with rituximab, indicating baseline risk in this population 1
- Maintain high index of suspicion for JC virus reactivation in any patient presenting with CNS abnormalities
Infectious complications:
- Severe infections are a major concern, particularly in immunosuppressed patients 1
- Respiratory tract infections are most common (5 cases in real-world data) 2
- Cytomegalovirus infection is a particular concern and accounted for half of infection events in one study 4
- Infusion reactions, particularly skin reactions, are the most common reason for treatment interruption (6 cases) 2
Common Pitfalls to Avoid
Do not delay rituximab in truly refractory cases—early use after conventional therapy failure (median 8 months) shows good outcomes 3
Do not assume all "polymyositis" will respond—the heterogeneous nature of inflammatory myopathies means some patients may not respond. In one study, 4 non-responders had their diagnoses corrected upon reassessment 6. Myositis overlap syndromes and anti-synthetase syndrome appear to respond better than pure polymyositis 6
Do not rely solely on CD19+ cell counts to determine need for re-treatment—clinical relapse does not always correlate with B-cell repopulation 7
Do not use rituximab as monotherapy initially—it should be combined with corticosteroids, which can be tapered after response 2, 3
Do not overlook infection prophylaxis—given the significant infection risk, particularly opportunistic infections, maintain vigilance throughout treatment 4
Expected Outcomes
- Muscle enzyme reduction: Significant reduction in CK levels typically occurs within 1-4 months, with normalization averaging 4.6 months 7
- Strength improvement: Improvement in Manual Muscle Testing scores and functional capacity within 6 months 1
- Steroid-sparing effect: Average daily prednisone dose decreases from approximately 15-17 mg to 4-5 mg 2, 7
- Sustained response: Clinical improvement maintained at 12-24 months in responders 2, 3